PB2240 EPIDEMIOLOGICAL DATA ON MYELOFIBROSIS IN ALBANIAN POPULATION (1999‐2018)

Background: Worldwide published epidemiological data on primary and secondary myelofibrosis (MF) are scarce, and multiple sources are needed to assess the disease burden in each country, in our country we have a lack of epidemiological data on MPD and MF. Aims: The aim of our study is to evaluate the annual incidence of Myelofibrosis in the Albanian population during the period of time from 1999‐2018. Methods: In our study the data were collected from the registries in our Service of Hematology and from the registries in the Department of Statistics, UHC “Mother Teresa” and were analyzed with SPSS 22.0. We have analyzed the data of all patients, age > 18 years, diagnosed with Myelofibrosis and hospitalized in the UHC “Mother Teresa” and in our Service of Hematology from 1999 to 2018. Results: During the interval 1999‐2018 in our hospital are diagnosed 108[100%] patients with MF, 54 pts (50%) males, and 54 pts (50%) female. The annual incidence of MF in Albania results around 0,22 new cases / 100,000 habitants per year. The median incidence of MF is about 5,7 new cases per year with a peak in 2013 (13 new cases) and an increase with respectively 10 new cases in 2017 and 15 new cases in 2018. The median age at the moment of the diagnosis resulted in 62,5 years old (interval range 25‐83 years old) Almost all the patients were on advanced stages of MF at the moment of the diagnosis (95%). Actually, 49 patients are on treatment with Ruxolitinib since 2015. Summary/Conclusion: A careful study, using standardized definitions of MF and complete assessment of patients including both primary and secondary MFs, should be performed to estimate the population aimed to receive novel era treatments for these neoplasms